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Abstract
Background: Insulin degrading enzyme (IDE) is responsible for the metabolism of insulin and plays a role in clearance of the
Ab peptide associated with Alzheimer’s disease. Unlike most proteolytic enzymes, IDE, which consists of four structurally
related domains and exists primarily as a dimer, exhibits allosteric kinetics, being activated by both small substrate peptides
and polyphosphates such as ATP.
Principal Findings: The crystal structure of a catalytically compromised mutant of IDE has electron density for peptide
ligands bound at the active site in domain 1 and a distal site in domain 2. Mutating residues in the distal site eliminates
allosteric kinetics and activation by a small peptide, as well as greatly reducing activation by ATP, demonstrating that this
site plays a key role in allostery. Comparison of the peptide bound IDE structure (using a low activity E111F IDE mutant) with
unliganded wild type IDE shows a change in the interface between two halves of the clamshell-like molecule, which may
enhance enzyme activity by altering the equilibrium between closed and open conformations. In addition, changes in the
dimer interface suggest a basis for communication between subunits.
Conclusions/Significance: Our findings indicate that a region remote from the active site mediates allosteric activation of
insulysin by peptides. Activation may involve a small conformational change that weakens the interface between two halves
of the enzyme.
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Introduction
Insulysin (EC 3.4.24.56; also referred to as insulin-degrading
enzyme or IDE) is a zinc metallopeptidase in the M16 family that
has been extensively studied because of its role in cellular insulin
degradation [1] and amyloid beta peptide catabolism [2,3]. The
importance of IDE in regulating insulin metabolism became
evident from studies of the GK rat model of type II diabetes
mellitus [4] where variants of IDE with reduced catalytic activity
were found to be associated with elevated insulin levels. In
addition, mice with homozygous deletions of IDE show a marked
decrease in insulin degradation [5], while IDE polymorphisms
have been associated with type 2 diabetes in humans [6]. Recently,
IDE has received considerable attention for its role in the
degradation of amyloid beta peptide [5,7,8], and a number of
studies have provided evidence for a genetic link between IDE and
Alzheimer’s disease [9,10,11,12]. IDE can degrade many bioactive
peptides of varying size in addition to insulin and the amyloid beta
peptide, although its role in regulating the levels other peptides in
vivo has not been established [13,14].
IDE exists predominantly as a dimer in equilibrium with
tetramers and to a lesser extent monomers [15,16]. It is unique
among the enzymes comprising the zinc metallopeptidase M16
family in that it exhibits allosteric kinetic behavior with substrate
peptides increasing its activity [16,17,18,19,20]. In addition, IDE
contains a distinct regulatory site first reported by Camberos and
coworkers [21] that binds nucleoside triphosphates and alters IDE
activity. This site was shown to be distinct from the active site and
to primarily interact with the triphosphate moiety [15]. Binding at
this site was shown to increase the rate of hydrolysis of some, but
not all, IDE substrates [15,22].
Crystal structures of human IDE (hIDE) complexed with
peptides [23,24,25,26] show that the enzyme consists of four
structurally related domains that adopt a clamshell-like structure
enclosing a large central chamber. Although the four domains
have the same overall fold, only the N-terminal domain, domain 1,
has an intact active site characteristic of zinc metallopeptidases.
Substrate binding requires a conformational change that opens the
central chamber, making internal binding sites accessible.
Substrates bind at the active site in a manner consistent with
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other zinc metallopeptidases, but larger peptides can also interact
with a distal binding site located in a separate domain of the
enzyme. The unliganded structure of hIDE was found to be in the
same closed conformation first observed in the peptide complex
structures, further indicating that the rate-limiting step for catalysis
is the conformational switch from the closed to open state [27].
We report here the crystal structures of rat IDE (rIDE) and a
catalytically compromised mutant form, rIDE-E111F. Surprising-
ly, the structure of the mutant enzyme shows peptide bound at
both active and distal sites. Probing the function of the distal site
by mutagenesis reveals its key role in the allosteric behavior of
IDE. Comparison of the rIDE and rIDE-E111F structures shows
small conformational changes upon peptide binding that likely
mediate allosteric activation.
Results
Overview of the rIDE Structure
The structures of wild type and E111F rIDE are very similar to
the published structures of peptide bound and unliganded human
IDE (hIDE) [23,24,25,26]. An alignment of wild type rIDE and
hIDE from the amyloid beta peptide complex (Protein Data Bank
code 2G47) yields an r.m.s.d. of 0.6 A˚ for 954 Ca atoms. The four
structurally similar domains each have an a+b fold and arrange to
form the same closed clamshell conformation as hIDE, with the N-
and C-terminal halves of the clamshell connected by a single
polypeptide chain. In the closed conformation, the two halves of
the clamshell are in contact with one another forming an enclosed
cavity, and the active site of the enzyme is accessible from this
internal substrate-binding chamber. The two rIDE structures show
similar local variations in isotropic atomic displacement factors (B
factors), although the values for the peptide bound enzyme are
generally higher, particularly for the first two domains (Fig. S1).
Location and Identification of Ligands Bound to
rIDE-E111F
The E111F mutation greatly reduces catalytic activity while
maintaining the ability to bind substrates [18]. We began work
with this mutant with the intention of using it to obtain structural
information on a variety of complexes between the enzyme and
substrate peptides. Interestingly, though, a difference (Fo-Fc) map
made with the rIDE-E111F data in the absence of added substrate
peptides revealed two regions of positive electron density located
within the central cavity of the enzyme (Fig. 1a) consistent with
bound peptide ligand. One segment of difference density was
found adjacent to the active site of the enzyme in domain 1, and
the second segment was found in the structurally equivalent region
of domain 2.
Two separate polypeptide chains were modeled into the ligand
density. The ligands were built as polyalanine, since density for the
peptide side chains was weak and fragmented. The first ligand was
modeled as an eight-residue peptide bound at the active site,
where it is positioned to interact with the enzyme through a series
of hydrogen bonds with the peptide backbone (Fig. S2). The
second ligand, located at the vestigial active site present in domain
2, the distal site, was modeled as a seven-residue peptide that is
also positioned to make a number of hydrogen bond interactions
with the enzyme (Fig. 1B). Both peptides adopt an extended
conformation, aligning along the last strand of the central sheet of
their respective interacting domains consistent with the usual
location of substrate peptides in zinc metallopeptidases [28]. For
the peptide in the distal site, the main chain carbonyl groups of
Gly339 and Leu359 as well as the side chain of Glu341 are in
position to interact with the N-terminal amino group. Addition-
ally, the side chains of Tyr609 and H332 and the main chain
carbonyl of Gly361 may make hydrogen bonds with the peptide
backbone.
To identify the bound ligand, samples were analyzed by mass
spectrometry at various steps during the purification of rIDE-
E111F: (1) the enzyme before proteolytic removal of the
polyhistidine fusion sequence used in purification, (2) purified
enzyme after elution from the Ni-NTA resin by proteolytic
removal of the polyhistidine sequence, and (3) imidazole eluate
Figure 1. The rIDE-E111F crystal structure. (A) Overview of the
structure. A ribbons representation of the enzyme is shown together
with polyalanine ligands (red sticks) built into difference density (Fo-Fc,
blue mesh, 2.0 sigma contour) at the active (A) and distal (D) sites.
Difference density was produced with phases from a refined model of
the enzyme prior to adding peptide models and so is not biased by the
peptide models. (B) Interaction of bound peptide with the domain 2
distal site of rIDE-E111F. The polyalanine peptide ligand is shown
(residues 1–4 of the seven residues in the model) in a stick
representation with difference density calculated as described above
(blue mesh, 2.0 sigma contour). Likely hydrogen bonds to the peptide
backbone are indicated by dashed lines.
doi:10.1371/journal.pone.0020864.g001
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from the metal affinity resin containing any polyhistidine fragment
remaining bound after IDE elution. No significant mass peaks
consistent with the observed ligands were observed before the
cleavage of the polyhistidine fusion sequence (Fig. 2A), suggesting
that the unknown ligand was not being co-purified from cell
lysates. However, a mass peak at 2895.8 Da was seen in the
sample after cleaving the fusion sequence with TEV protease to
elute the enzyme from the Ni-NTA resin (Fig. 2B). No such peak
was observed for the wild type rIDE purified in the same manner
or in a control containing only the TEV protease. A sample
containing N-terminal polyhistidine fusion sequence eluted from
the Ni-NTA agarose gave a peak at 2896.2 Da (Fig. 2c), closely
matching the peak in the enzyme sample. MS/MS analysis of the
2896.2 Da peak gave 18 of 20 expected b-ions (Fig. S3a), 12 of 21
expected y-ions, and at least 3 of 22 expected y*-ions (Fig. S3b),
allowing unambiguous identification of the ligand sequence (Fig.
S3c). This result is consistent with the bound ligand being the
polyhistidine fusion sequence after removal of its N-terminal
methionine residue and acetylation of the new N-terminal serine
(N-Ac-SYYHHHHHHDYDIPTTENLYFQ, expected mass of
2895.9 Da). Posttranslational modification of this type for
polyhistidine fusion sequences of proteins expressed in insect cells
has been noted previously [29]. These data indicate that the
ligands observed in the crystal structure are the cleaved
polyhistidine fusion sequence bound to rIDE-E111F. Given the
positions of the two modeled peptides, it is possible that they
represent two portions of a single polyhistidine fusion sequence
with the joining residues disordered and therefore not visible in the
crystal structure. This type of binding at the active and distal sites
of IDE has been seen with other peptides [26]. It is also possible,
however, that different peptides are bound at the active and distal
sites, with only eight of 22 residues ordered in the active site
peptide and seven of 22 residues ordered in the distal site peptide.
Bound peptides are presumably not seen associated with wild type
rIDE because the polyhistidine fusion sequences are degraded by
the active enzyme.
Mutations in the Distal Site Eliminate Allosterism
Our previous work showed that IDE displays allosteric kinetics
and that small peptides can act as activators of the enzyme
[16,17,18,19,20]. The finding in this study of peptide ligand bound
to the distal site, as well as similar findings by others [24,26],
suggested that this site may be involved in mediating the allosteric
regulation of rIDE. To test this hypothesis, we mutated several
distal site residues in close proximity to the bound peptide. Three
mutant versions of rIDE, Y609F, V360S, and I374S (see Fig. 1)
were prepared and the mutant constructs analyzed for allosteric
kinetics and activation by a small peptide. The side chain of Y609
is positioned to hydrogen bond to the backbone of bound peptide
as noted previously, and V360 and I374 are positioned to interact
with side chains of a peptide bound at the distal site.
Initial velocity versus substrate concentration plots (Fig. 3A) for
activity on the fluorogenic peptide substrate Abz-GGFLRKHGQ-
EDDnp show that the allostery present in the wild type enzyme is
lost in each of the three distal site mutants. Fitting the data with a
sigmoidal function gives Hill coefficients (Table 1) of 1.80 for the
wild type enzyme and 1.04, 1.07, and 1.12 for the Y609F, V360S,
and I374S mutants. Vmax values for the mutants were all
decreased approximately 10 fold relative to wild type, consistent
with the loss of activation, while apparent Km values remain
roughly the same. Heterotropic activation with the small peptide
bradykinin (approximately 4-fold for the wild type enzyme) is also
lost in all three mutants (Fig. 3B), showing directly the absence of
allosteric activation.
ATP also acts as a heterotropic activator of IDE, increasing the
cleavage rate of the fluorogenic peptide substrate Abz-
GGFLRKHGQ-EDDnp more than 40 fold [15]. However,
ATP activation of the V360S mutant was reduced to 8 fold, and
activation by ATP was not significant for the I374S and Y609F
mutants (Fig. 3C). In all three mutants, enhancement of TNP-ATP
fluorescence emission indicates that they still bind the ATP analog,
although with lower affinity than the wild type enzyme (Table 1,
Fig. S4). However, the degree of TNP-ATP fluorescence
enhancement is diminished in the mutants, as is the blue shift in
the emission peak observed upon binding to the wild type enzyme
Figure 2. Mass spectrometry identification of ligand bound to
rIDE-E111F. (A) MALDI-TOF analysis of purified rIDE-E111F before
removal of the polyhistidine fusion sequence. Only matrix peaks are
observed. (B) MALDI-TOF analysis of rIDE-E111F after cleavage of the
polyhistidine fusion sequence. A peak representing bound ligand is
evident. (C) MALDI-TOF analysis of the polyhistidine fusion tag eluted
from Ni-NTA agarose resin after normal rIDE-E111F purification. This
peak matches the peak representing ligand bound to purified rIDE-
E111F in panel B and is consistent with the expected mass of the fusion
sequence.
doi:10.1371/journal.pone.0020864.g002
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(Figs. 4). These differences in the emission spectrum of bound
TNP-ATP indicate a change in the local environment in the
mutants relative to the wild type enzyme, which may result from
the loss or alteration of a conformational change associated with
allosteric activation.
Structural Basis for Allosterism
Comparison of the ligand free rIDE structure and the rIDE-
E111F structure with ligand bound at the distal and active sites
suggests a likely structural basis for allosterism. Alignment of the
two enzyme structures on Ca positions in the N-terminal halves
(domains 1 and 2) of the molecules reveals a difference in the
relative positions of the C-terminal portions of the molecule
(Fig. 5A, B; SI Movie S1). Binding ligand appears to induce a small
shift of domains 3 and 4 relative to domains 1 and 2. While the
observed structural rearrangement is small, with a maximum
amplitude of 1.5 A˚ (r.m.s.d. of 0.58 A˚ for domain 3 and 4 main
chain atoms), it is largely concerted, with nearly all Ca positions
moving in the same direction (Fig. 5B). Interactions across the
interface between the N- and C-terminal halves of the molecule
are affected (Table S1, Fig. 5C). The number of residues involved
in the interface increases from 133 in the wild type enzyme to 135
in the mutant, although the total solvent accessible surface area
buried decreases slightly from 2402 A˚2 for the wild type to
2324 A˚2 for the mutant. Overall, both the total number of
hydrogen bonds and salt bridges across the interfaces decreases in
the peptide bound mutant (wild type: 29 H-bonds, 13 salt bridges;
IDE-E111F: 28 H-bonds, 11 salt bridges). It is important to note
that while the total number of residues and polar contacts change
modestly on peptide binding, there are even more extensive
differences in particular residues involved in the interface and
those making polar contacts, as is evident on examination of Table
S1.
Given the number of changes in the interface between the two
halves of the molecule, its stability is also likely altered.
Destabilizing the interface would increase partitioning of the
enzyme into an open conformation (with the two halves hinging
about the chain linking domains 2 and 3) necessary for substrate
binding and product release. Since it is believed that the rate of
adopting the open conformation limits IDE activity [26],
weakening the interface by peptide binding in the distal site (and
possibly the active site) would be expected to activate the enzyme.
The relative shift of the two halves of the enzyme is also is evident
when comparing the liganded and unliganded hIDE structures
determined by Tang and coworkers [24,26,27], providing
additional evidence for the significance of the observation in this
study. As already noted, the crystallographic thermal factors for
the first two domains of the ligand bound mutant are consistently
higher than those for the unliganded enzyme (Fig. S1). This
Figure 3. Effects of distal site mutations. (A) Comparison of the kinetics of wild type IDE with the distal site mutants. Activity was measured with
varying amounts of Abz-GGFLRKHGQ-EDDnp substrate as indicated. Either hyperbolic (Michaelis-Menten equation) or sigmoidal curves (Hill equation)
were fit to the data. (B) Effect of bradykinin on the activity of wild type IDE and the distal site mutants. (C) Activation of wild type IDE and distal site
mutants by ATP. Relative activity is the fold activation above the level of the wild type enzyme alone.
doi:10.1371/journal.pone.0020864.g003
Table 1. Kinetics of IDE and distal site mutants.
Wild Type Tyr609Phe Val360Ser Ile374Ser
Vmax (nmol/min/
mg)
35.561.6 2.660.56 2.0160.08 3.4560.22
Hill coefficient 1.860.16 1.0460.14 1.0760.30 1.1260.2
Km (mM) 15.8761.19 6.8661.18 8.6160.81 8.5+1.74
KD
TNP-ATP (mM) 1.060.1 2.060.3 3.760.8 2.160.5
doi:10.1371/journal.pone.0020864.t001
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difference may reflect a higher relative mobility of the two halves
of the peptide bound enzyme, which would be consistent with a
weakening of the interface.
In addition to the largely translational shift between the two
halves of the enzyme, other changes in conformation between the
unliganded enzyme and rIDE-EIIIF are evident. Elements within
the active site domain (domain 1) rotate with respect to the
remainder of the domain as well as domains 2–4 (Fig. 5D). The
rotation, which occurs roughly about an axis through the domain
1-domain 2 interface, involves helical elements on one side of the
central sheet of the domain. In particular, helices 1 (containing the
catalytic and two zinc ion binding residues) and 2 (residues 105–
135) as well as helices 3–7 (residues 157–247) rotate largely as a
rigid body (,5u). Helices 3–7 are positioned over the active site
shielding it from solvent. Since the helical elements that rotate
border on the substrate-binding site, it is possible that the change
in orientation accompanies peptide binding at the active site in
rIDE-E111F. Interestingly, helices 2 and 4 form part of the
interface between the two halves of the molecule, largely
interacting with elements in domain 4. Thus the conformational
change in domain 1 may play a role in the shift in the two halves
between the unliganded and ligand-bound IDE structures.
Alternatively, the change in the interface might drive the
conformational change in the active site domain.
One other conformational change occurs between the un-
liganded wild type enzyme and rIDE-E111F. IDE functions as a
dimer [15,16,26,30], and one of the contacts in the human IDE
crystals has been identified as the dimer interface [20,26]. This
interface has also been confirmed as the dimer interface with the
rat enzyme [20]. In rIDE-E111F, the subunits undergo a relative
rotation compared to the unliganded enzyme (Fig. 6; SI Movie
S2). This rotation occurs about an axis roughly orthogonal to the
dimer axis, giving maximum shifts of about 2.5 A˚ when the
structures are aligned on one monomer. The changes reduce the
number of residues involved in the interface (per monomer) from
45 in the wild type enzyme to 42 in the mutant (residues Pro760,
Tyr766, and Phe1005 no longer participating), although the total
surface area actually increases slightly from 1392 A˚2 in the wild
type to 1432 A˚2 in the mutant (Table S2). The pattern of polar
contacts is also altered somewhat, with differences at positions 586,
706, 756, 914, 1001, and 1009. In total, the number of interfacial
hydrogen bonds changes from 14 in the wild type to 12 in the
mutant, and the number of salt bridges remains at four, although
different residues are involved. Overall, the conformational
changes between the wild type and peptide-bound mutant IDE
do not greatly disturb the packing in the crystal (Fig. S5, Table S3).
Discussion
The results of the present study illuminate the mechanism of
allosteric regulation in IDE. The crystal structure of rIDE-E111F
shows peptide binding contacts at two distinct locations, the active
site in domain 1 and a distal site located in domain 2. Changing
the distal site through mutagenesis reduces the activity of the
enzyme and converts its kinetics from allosteric to classical
Michaelis-Menten. Mutations at the distal site also eliminate the
previously observed heterotropic activation produced by small
peptide substrates [16] and reduce or eliminate activation by ATP
[15].
In earlier work, we noted that the substrate bradykinin acts as
an activator of the reaction of IDE with Abz- GGFLRKHGQ-
EDDnp, while other peptide substrates, such as b-endorphin and
dynorphin A(1–17), show activation at low concentrations and
inhibition at higher concentrations [16]. This can be explained by
Figure 4. Fluorescence spectra of TNP-ATP bound to wild type IDE and the distal mutants. Fluorescence emission spectra of 10 mM TNP-
ATP in 50 mM Tris-HCl, pH 7.4, was measured in the presence of 1.5 mM of each wild type IDE and the indicated IDE distal mutants. Fluorescence
spectra were recorded with a lexc = 403 nm on a Perkin-Elmer LS55 Luminescence Spectrometer.
doi:10.1371/journal.pone.0020864.g004
Insulysin Allosteric Site
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20864
their relative affinity for the distal site versus the active site. The
higher the affinity for the distal site relative to the active site the
more the peptide acts as a pure allosteric activator, while binding
at the active site produces competitive inhibition. It is interesting to
note that the crystal structure of IDE in the presence of bradykinin
[24] shows peptide bound only at the distal site. This observation is
consistent with bradykinin having a higher affinity for the distal
site than the active site and therefore acting as a pure activator.
IDE crystallizes in a closed conformation in which the active site
and substrate binding surfaces are inaccessible, and it seems likely
that it is present primarily in the closed form in solution. The
enzyme therefore must undergo a hinge-like motion to an open
conformation in order to bind substrate and release products
[26,27]. Tang and coworkers [26,27] have shown that destabiliz-
ing the interface between the N- and C-terminal halves of IDE by
mutagenesis increases its activity, indicating that adopting an open
conformation is rate limiting. The conformational change induced
by peptide binding seen in this study suggests that allosteric
activation occurs by destabilizing the N- and C-terminal domain
interface. For small substrates, peptide binding at the distal site
increases the population in the open conformation, enhancing
both substrate binding and product release. Larger substrates can
bind at both the active and distal sites simultaneously, and the
enzyme does not therefore exhibit allosteric kinetics or heterotro-
pic activation with these molecules [16].
Since IDE functions as a dimer [16,26,30], a relevant question is
whether activation occurs within or between subunits. Free
monomeric IDE does not show allosteric kinetics and is not
activated by added small peptides, indicating that the dimer is
required for allostery [20]. At first glance, these results would seem
to suggest that activation occurs across the dimer interface.
However, work with mixed dimers carrying combinations of
mutations at the active or distal sites in one or both subunits
demonstrates that the primary allosteric effect occurs within each
Figure 5. Basis for allosteric activation. (A) Plot of r.m.s. main chain atom positional differences between unliganded IDE and rIDE-E111F with
bound peptide ligands at the active and distal sites. Boundaries for domains 1–4 are indicated by the vertical dashed lines. The two structures were
superimposed on Ca positions in domains 1 and 2. (B) A porcupine type diagram illustrating the conformational change between unliganded IDE and
rIDE-E111F superimposed on domains 1 and 2. Cones indicate the direction and magnitude of differences between Ca positions. Domains are
labeled. The size of the cones has been scaled by a factor of 3 relative to the dimensions of IDE to make the conformational change visible in a small
diagram. (C) Example of a change in an interface contact between two halves of IDE comparing aligned unliganded IDE (green) and rIDE-E111F (cyan)
structures. (D) Conformational changes in the active site domain (domain 1). Superimposed structures of unliganded IDE (green) and rIDE-E111F
(cyan) are shown. Residues at the active site are shown in a stick representation, and the zinc ion cofactor is drawn as a yellow sphere. (E) Model of
IDE allosteric activation. In the absence of bound peptide at either the active or distal sites, the equilibrium between the closed and open forms of
IDE (KU) is shifted toward the closed form, which prevents substrate binding and product release. With peptide bound at the distal site (and possibly
the active site), the equilibrium (KL) shifts to increase the population in the open form, enhancing peptide binding and product release.
doi:10.1371/journal.pone.0020864.g005
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subunit of the dimer [18,31]. We therefore favor a model in which
binding of peptide to the distal site induces a conformational
change in the same monomer that shifts the equilibrium toward
the open form (Fig. 5E). The conformational change is, however,
dependent on the monomer participating in dimer contacts with
its partner subunit. Without this interaction, peptide binding at the
distal site does not greatly alter the equilibrium between open and
closed forms. A full scheme diagramming this model for IDE
activation is given in Fig. S6.
How does peptide binding drive alteration of the interface
between monomer halves? At the distal site, bound peptide lies
close to the hinge region connecting the two halves of the
molecule. It also interacts with Tyr609 from domain 3, which is
located on the opposite side of the hinge. Binding of peptide in this
region might influence the conformation of the hinge region and
surrounding interface surfaces by direct interactions with residues
on either side of the hinge. It is also possible that more general
electrostatic effects, for example peptide binding changing the
charge-charge interactions between the halves of the molecule,
play a role in altering the interface.
Although activation within a monomer likely accounts for IDE
allostery, previous data with mixed dimers indicate that some
communication between the subunits occurs [16]. In particular,
mutations at the active site of one monomer appear to affect the
activity of the other monomer, and it is possible that this occurs in
the E111F mutant. The observed conformational shift at the dimer
interface between ligand free wild type enzyme and ligand bound
rIDE-E111F reported here suggests a possible structural basis for
this communication. The conformational change in the active site
domain (domain 1) of rIDE-E111F observed in this study may
induce changes in the dimer interface, which in turn cause
corresponding changes in the active site of the other subunit. Since
the active site domains of the two subunits do not participate in the
dimer contacts, conformational changes may be transmitted
through domain 4, which is in close contact with the active site
domain and forms a large part of the dimer interface. If so, the
changes in that domain are too subtle to be discerned by
comparing the two structures described in this report. It should be
noted that there is some evidence that bound ligands affect the
oligomerization state of IDE [15,16,18]. The possibility remains
open, therefore, that the conformational shifts observed in this
study changes the affinity of the dimer interface and affect activity
by altering oligomerization. We also note that the absence of the
metal ion in the peptide bound mutant enzyme could potentially
play a role in altering conformation. However, loss of the metal ion
in zinc metallopeptidases has been found to not alter structure
[32], and it seems unlikely that it is influencing the observed
differences in conformation.
It has previously been established that polyanions, including
ATP, strongly activate IDE toward hydrolysis of small peptides by
binding to a site distinct from the active site [15]. The finding that
mutations in the distal site greatly reduce or eliminate activation
by ATP implies a mechanistic linkage between the two forms of
activation. A difference in the bound TNP-ATP emission
spectrum caused by mutations in the distal site indicates that
changes at that site affect the environment of the ATP binding site.
The distal site does not have a concentration of basic residues and
therefore seems an unlikely location for ATP binding, suggesting
that the effect of mutations there may propagate to another site on
the enzyme. One possibility is that the interface between the N-
and C-terminal halves of IDE is affected by ATP binding and that
mutations at the distal site affect the ability of bound ATP to
induce these changes. Further structural studies will be needed to
explore this interesting link between the two activating sites.
Identification of the allosteric site of IDE and possible
mechanisms of activation lays the groundwork for further
investigations into the activity of this unusual and important
enzyme. In addition, this work provides a framework for attempts
to develop selective activators of IDE or modified versions of the
Figure 6. Changes at the dimer interface. (A) Superimposed dimer
structures of unliganded IDE (green) and rIDE-E111F with peptide
ligand bound at the active and distal sites (cyan). Dimers are aligned
based on Ca positions of one monomer (molecule 1). (B) Porcupine
type representation of the change in Ca positions between the two
structures aligned on molecule 1. Cones represent the magnitude and
direction of Ca positional changes. The size of the cones has been
scaled by a factor of 2.5 relative to the dimensions of IDE to emphasize
the conformational shifts. The orientations of the molecules are the
same as those in panel A.
doi:10.1371/journal.pone.0020864.g006
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enzyme that may be used as therapeutics for the treatment of
Alzheimer’s disease and other disorders.
Materials and Methods
IDE Expression and Purification
Native rat IDE (rIDE, residues 42–1016, 95% identical and
98% similar to the human ortholog), E111F-rIDE, and IDE distal
site mutants were expressed as hexahistidine fusion proteins in SF9
insect cells [18,33]. All enzymes produced begin at methionine 42,
which is believed to be the in vivo start site [34], and extend
through the native C-terminal residue leucine 1019. Selenome-
thionine incorporation [35] was achieved by pre-incubating Sf9
insect cells with rIDE-baculovirus for 10 hours in methionine-
depleted SF-900 II SFM media (Invitrogen). Selenomethionine
was then added to the media and the cells were allowed to
incubate another 72 hours before harvesting.
IDE was purified (Fig. S7) using HIS-select Ni-NTA agarose
(Sigma) utilizing the N-terminal hexahistidine affinity tag (hex-
ahistidine sequence and a linker containing a TEV protease
cleavage site), eluting by proteolytic removal of the hexahistidine
sequence with TEV protease [18,33]. Protein was estimated using
Coomasssie Blue Reagent (BioRad) with BSA as a standard.
Preparation of IDE Distal Site Mutants
IDE distal site mutants were generated by site-directed
mutagenesis using the QuikChange kit (Stratagene) with the wild
type rIDE cDNA in pFastBac HTb as a template. Oligonucleo-
tides used for mutagenesis with the base changes in bold and
underlined were:
Y609F:
Forward 59 - CTCAACGACTATGCATTTGCAGCAGAG-
CTAGCA-39
Reverse 59 - TGCTAGCTGTGCTGCAAATGCATACTC-
GTTGAG – 39
V360S:
Forward 59 - TGGGTAAACACCCTGTCTGGGGGACA-
GAAGGAA- 39
Reverse 59 – TTCCTTCTGTCCCCCAGACAGGGTGTT-
TACCCA - 39
I374S:
Forward 59 – GGTTTTATGTTTTTTTCCATTAATGTG-
GACTTA- 39
Reverse 59 – TAAGTCCACATTAATGGAAAAAAACA-
TAAAACC- 39
Crystallization and Structure Determination
Enzyme at 8 mg/ml in 50 mM Tris 7.4, 1 mM DTT, and
100 mM NaCl was crystallized by sitting drop vapor diffusion. Protein
was mixed 1:1 with well solution containing 100 mM sodium citrate
pH 6.5, 100 mM ammonium acetate, and 20% PEG 4000, and
crystals grown at 20 or 22uC. Full-sized (0.2 mm longest dimension)
crystals grew reproducibly within two weeks. Crystals produced in this
manner diffracted only to low resolution, but dehydration [36] by brief
(1–5 second) transfer to 50% PEG 4000 prior to flash cooling in liquid
nitrogen gave high resolution diffraction.
Data were collected at the Southeast Regional Collaborative
Access Team (SER-CAT) 22-ID and 22-BM beamlines at the
Advanced Photon Source (APS), Argonne National Laboratory.
Se-MAD data sets were collected at both SERCAT 22-ID at APS
and X25A at the National Synchrotron Light Source (NSLS)
through each of their mail-in crystallography programs. X-ray
data were processed using HKL2000 [37] and the space group of
the crystals found to be C2 with one molecule per asymmetric unit
and cell parameters of a = 115.8 A˚, b = 71.2 A˚, c = 114.6 A˚,
a= 90.00, b= 92.46, and c= 90.00 for the wild type enzyme
and a = 115.5 A˚, b = 71.0 A˚, c = 114.4 A˚, a= 90.00, b= 92.97,
and c= 90.00 for the E111F mutant. The data sets were checked
for possible pseudomerohedral twinning, but no significant
twinning was detected using PHENIX XTRIAGE [38].
Molecular replacement was performed using Phaser [39] and
CCP4 [40] using the deposited hIDE structure in complex with the
amyloid beta peptide (Protein Data Bank code 2G47) as a search
model. The Rfree value of the model after molecular replacement
was 0.42. Anomalous density maps calculated using phases from
selenomethionine data showed peaks consistent with methionine
residue positions in the model, confirming the molecular replace-
ment solution. Model building and refinement using the molecular
replacement solution was done using COOT [41] and REFMAC5
[42]. Water picking was done using PHENIX [38,43,44] with
manual editing of all additions in COOT. Six TLS groups,
determined using the TLS Motion Server [45], were used in atomic
displacement refinement for each structure. Final refinement was
performed using CNS [46] and PHENIX. Molecular structure
figures were made using PyMOL (http://www.pymol.org). The final
wild type model contains residues 42–963 and residues 980–1011
with 232 ordered solvent molecules and one zinc ion. The rIDE-
E111F model contains residues 42–965 and 978–1011 with 185
ordered solvent molecules and two peptides, one comprised of seven
alanine residues and the other of eight alanine residues. Data and
refinement statistics are listed in Table 2 and Ramachandran plots,
made with PROCHECK [47], are provided in Fig. S8. Protein-
protein interfaces were analyzed using the program PISA [48].
Identification of Bound Ligand
The identity of the unknown ligand observed in the rIDE-
E111F structure was determined by MALDI-TOF analysis using a
crystallization drop from which crystals were harvested. In
addition, a fresh sample of rIDE-E111F was analyzed at specific
steps during purification. To verify that the unknown ligand was
not introduced with the TEV protease added during purification,
a TEV sample was also analyzed as a control. MS/MS analysis
was performed using the precursor peak at 2896 from the HIS-tag
alone sample in order to determine sequence information.
MALDI-TOF and MS/MS experiments (scan range 500–4000)
were performed at The Scripps Center for Mass Spectrometry and
at The University of Kentucky Proteomics Core Facility. Data
analysis was performed using MS-Product [49] and Data Explorer
Software (Applied Biosystems).
Enzyme Activity Assay
The activity of IDE was measured by following the increase in
fluorescence upon hydrolysis at the L-R bond of the fluorogenic
peptide Abz-GGFLRKHGQ-EDDnp on a SpectraMax Gemini XS
fluorescence plate reader using an excitation wavelength of 318 nm
and emission wavelength of 419 nm. Reactions were carried out in
200 ml volumes containing 50 mM Tris-HCl, pH 7.4, 1.92 mg of wild
type rIDE, 4.6 mg of rIDE-V360S, 4.3 mg rIDE-I374S, or 1.63 mg of
rIDE-Y609F. For measurements of activation by bradykinin, IDE
activity was determined with 10 mM Abz-GGFLRKHGQ-EDDnp as
substrate in 50 mM Tris-HCl buffer, pH 7.4. The amount of protein
was 0.5 mg for wild type rIDE and 5 mg for each of the IDE distal-site
mutants. Data were analyzed using Softmax 4.0 (Molecular Devices)
and kinetic parameters calculated with Prism (Graphpad Software)
[50,51]. Specific activity with the Abz-GGFLRKHGQ-EDDnp
substrate is 8,131 nmol/min/mg for the wild type enzyme and
5.2 nmol/min/mg for the E111F mutant [18]. Under these assay
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conditions, both wild type and mutant rIDE are almost completely
dimeric [31].
Fluorescence Measurements
Fluorescence measurements of TNP-ATP binding were performed
on a Perkin-Elmer LS55 Luminescence Spectrometer. Titrations
were monitored at an excitation wavelength of 403 nm and emission
wavelength of 547 nm. The temperature of the sample was
maintained at 2060.1uC by circulating thermostatically controlled
water through the cuvette holder. Assays were conducted in 200 mL
reaction mixtures containing 50 mM Tris-HCl, pH, 7.4, 10 mM Abz-
GGFLRKHGQ-EDDnp as substrate, and 0.5 mg wild type rIDE,
2.3 mg rIDE-V360S, 2.0 mg rIDE-I374S or 1.62 mg rIDE-Y609F
and the indicated concentration of ATP. The fluorescence of TNP-
ATP was subtracted from the total fluorescence of enzyme+TNP-
ATP to yield specific fluorescence enhancement (DF).
Supporting Information
Figure S1 Isotropic thermal factors from rIDE crystal structures.
The isotropic thermal factors for each residue (average of main
chain atoms) are plotted versus residue number. Values for the
wild type unliganded IDE model are in filled circles, and values for
the E111F IDE mutant with bound peptides are in open triangles.
(TIF)
Figure S2 Interaction of bound peptide with the active site
(domain 1). The polyalanine peptide is shown as a stick
representation in difference density (blue mesh, 2.0 sigma
contour). Hydrogen bonds to backbone groups in residues 1, 5,
6,and 7 are indicated by dashed lines.
(TIF)
Figure S3 Identity of ligand bound to rIDE-E111F. (A) MS/MS
analysis of the precursor peak 2896.2017 (*) with observed b-ion
peaks labeled. (B) MS/MS analysis of the precursor peak 2896.2017
(*) with observed y-ion and y*-ion peaks labeled. (C) Schematic of
the expected b- and y-ions which may be observed upon
fragmentation of the HIS-tag with MS/MS analysis (top). Summary
of the results from the MS/MS analysis of the 2896.2017 precursor
peak (bottom; np indicated no peaks were observed).
(TIF)
Figure S4 ATP analog binding to wild type and distal site
mutant IDE. The fluorescence increase on binding of (2,4,6-
Table 2. Summary of crystallographic data and model refinement.
unliganded IDE rIDE-E111F
Crystallographic data
Wavelength (A˚) 0.9718 1.0000
Resolution (A˚) 50-2.08 50-2.14
Last shell (A˚) 2.16-2.08 2.24-2.14
Average redundancy (last shell) (%) 4.6 (2.9) 2.8 (2.0)
Rmerge (last shell) (%) 0.10 (0.47) 0.088 (0.41)
I/sI (last shell) (%) 11.9 (2.1) 14.96 (3.98)
Completeness (last shell) (%) 97.5 (87.9) 98.7 (99.6)
Refinement
Resolution (A˚) 50-2.08 50-2.14
Number of reflections included in refinement 52364 47228
Rwork/Rfree 0.19/0.26 0.19/0.26
estimated coordinate error (A˚)a 0.31 0.33
r.m.s.d. bond lengths (A˚) 0.008 0.009
r.m.s.d. bond angles (u) 1.11 1.16
r.m.s.d. chirality (u) 0.07 0.08
r.m.s.d. planarity (u) 0.005 0.005
r.m.s.d. dihedral angles (u) 14.9 16.4
Bb r.m.s.d. bonded atoms 3.8 4.3
Average B for all protein atoms (A˚2) 39 56
Average B for ordered solvent (A˚2) 37 48
Number of protein molecules in the asymmetric unit 1 1
Number of protein residues in the asymmetric unit 954 958
Number of peptide residues in the asymmetric unit 0 15
Number of protein and peptide atoms in the asymmetric unit 7802 7909
Solvent content (%) (Matthews coefficient) 41.8 (2.1) 41.7 (2.1)
Number of solvent molecules 232 185
Number of metal ions 1 0
aMaximum likelihood method in Phenix [43,44].
bIsotropic thermal factor.
doi:10.1371/journal.pone.0020864.t002
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trinitrophenyl)ATP (TNP-ATP) is plotted for the indicated IDE
constructs as a function of ligand concentration. Data were fit to a
hyperbolic one site binding mechanism.
(TIF)
Figure S5 Packing in the rIDE crystals. Molecules in a unit cell
(black outline) are shown as C trace worms in two orthogonal
views for the wild type unliganded and E111F mutant-peptide
complex crystals. Molecules used to generate symmetry mates are
shown in green and cyan for the wild type unliganded IDE and
E111F mutant-peptide complex, respectively. Symmetry related
molecules are shown in blue, wild type, and orange, liganded
mutant.
(TIF)
Figure S6 Allosteric mechanism of IDE. A mechanistic model
based on functional and structural observations is given. The two
halves (domains 1 and 2, and domains 3 and 4) of an IDE
monomer are shown schematically in closed and open forms with
schematic representations of bound substrates and ligands. The
active (A) and distal (D) sites are labeled. Substrate peptide is
shown as a narrow zigzag line, and allosteric peptide as a heavy
zigzag line. In the absence of bound ligand, the closed form of the
molecule predominates (equilibrium K1). Binding substrate shifts
the population distribution even more toward the closed form (K3)
because the peptide interacts with both halves of the enzyme. The
subsequent cleavage step is fast, but product release is likely rate
limiting, since the closed form is still strongly favored (K4). Binding
of peptide at the distal site alters the interface to increase the
proportion of enzyme in the open conformation (K6). Substrate
binding (K7) is therefore likely enhanced. Importantly, product
release is also enhanced by the shift in distribution toward the
open conformation (K9), effectively activating the enzyme at the
substrate concentrations used for assays.
(TIF)
Figure S7 Enzyme purification. A Coomassie-stained SDS
polyacrylamide gel is shown with wild type or mutant enzyme at
different stages of purification: lanes 1 and 5, crude lysate; lanes 2
and 6, flow through from nickel affinity column; lanes 3 and 7,
20 mM imidazole elution; lanes 4 and 8, 200 mM imidazole
elution (final purity).
(TIF)
Figure S8 Crystal structure main chain torsion angle plots.
Ramachandran plots of main chain phi and psi angles are shown
for wild type unliganded (A) and E111F mutant-peptide complex
(B). Summary statistics are shown beside each plot.
(TIF)
Table S1 Interface between the N- and C- terminal halves of
wild type and peptide bound E111F mutant IDE.
(PDF)
Table S2 Dimer interface of wild type and peptide bound
E111F mutant IDE.
(PDF)
Table S3 Crystal contact interfaces of wild type and peptide
bound E111F mutant IDE.
(PDF)
Movie S1 Monomer conformational change. The enzyme is
shown in a backbone worm representation converting from the
wild type unliganded form to the rIDE-E111F liganded form. The
orientation is the same as that in Fig. 1A.
(MOV)
Movie S2 Dimer conformational change. The enzyme dimer is
shown in a backbone representation converting from the wild type
unliganded form to the rIDE-E111F liganded form. The orientation
is the same as that in the upper image of Fig. S1 panel A.
(MOV)
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